药品详细
Procyclidine(丙环定)
化学结构式图
中文名
丙环定
英文名
Procyclidine
分子式
C19H29NO
化学名
1-cyclohexyl-1-phenyl-3-(pyrrolidin-1-yl)propan-1-ol
分子量
Average: 287.4397
Monoisotopic: 287.224914555
Monoisotopic: 287.224914555
CAS号
77-37-2
ATC分类
N04A 未知
药物类型
small molecule
阶段
approved
商品名
Arpicolin;Elorine;Kemadrin;Kemadrine;Lergine;Metanin;Osnervan;Procyclid;Procyklidin;Prosyklidin;Spamol;Triciclidina;Triciloid;Tricoloid;Tricyclamol;Vagosin;
同义名
Prociclidina [INN-Spanish];Procyclidinum [INN-Latin];
基本介绍
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. [PubChem]
生产厂家
- Monarch pharmaceuticals inc
封装厂家
参考
| Synthesis Reference | Not Available |
| General Reference |
|
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
PARKINSON 帕金森氏症;
药理
| Indication | For the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents. |
| Pharmacodynamics | Procyclidine has an atropine-like action on parasympathetic-innervated peripheral structures including smooth muscle. It's antispasmodic effects are thought to be related to the blockage of central cholinergic receptors M1, M2 and M4. It is used to treat symptomatic Parkinsonism and extrapyramidal dysfunction caused by antipsychotic agents. |
| Mechanism of action | The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation. |
| Absorption | Not Available |
| Volume of distribution | Not Available |
| Protein binding | Approximately 100% bound to albumin. |
| Metabolism |
Not Available
|
| Route of elimination | Not Available |
| Half life | Not Available |
| Clearance | Not Available |
| Toxicity | LD50=60 mg/kg (IV in mice) |
| Affected organisms |
|
| Pathways | Not Available |
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Donepezil | Possible antagonism of action |
| Galantamine | Possible antagonism of action |
| Haloperidol | The anticholinergic increases the risk of psychosis and tardive dyskinesia |
| Tacrine | The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Procyclidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. |
| Trimethobenzamide | Trimethobenzamide and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. |
| Triprolidine | Triprolidine and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. |
| Trospium | Trospium and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. |
食物相互作用
Not Available
收藏